众生药业(002317) - 2024 Q1 - 季度财报

Financial Performance - The net profit for the current period is 48,710,926.21, a decrease from 138,047,060.65 in the previous period, representing a decline of approximately 64.7%[26] - The total profit for the current period is 59,116,625.23, down from 161,536,199.78 in the previous period, indicating a decrease of about 63.4%[26] - The operating profit for the current period is 59,273,889.43, compared to 161,584,545.29 in the previous period, reflecting a decline of approximately 63.3%[26] - The total comprehensive income for the current period is 49,316,011.34, down from 138,912,660.55 in the previous period, representing a decrease of about 64.5%[27] - The basic earnings per share for the current period is 0.06, compared to 0.17 in the previous period, indicating a decline of approximately 64.7%[27] - Net profit attributable to shareholders for Q1 2024 was ¥51,293,866.37, down 63.20% from ¥139,376,205.22 year-on-year[43] Revenue and Costs - Total operating revenue for Q1 2024 was CNY 641,123,852.50, a decrease of 14.1% compared to CNY 746,765,187.01 in the same period last year[23] - Total operating costs for Q1 2024 were CNY 564,699,468.91, down 6.2% from CNY 602,236,055.17 in Q1 2023[23] Cash Flow and Liquidity - The net cash flow from operating activities improved by 45.54%, from -CNY 145,894,988.66 to -CNY 79,448,307.60, mainly due to last year's early procurement of raw materials[5] - The cash flow from operating activities shows a net outflow of -79,448,307.60, an improvement from -145,894,988.66 in the previous period[27] - Cash and cash equivalents at the end of the period were CNY 954,601,790.51, down 23.7% from CNY 1,252,043,320.29 at the beginning of the period[16] - The net cash flow from investment activities was ¥88,719,114.27, a decrease from ¥261,566,208.84 in the same period last year[43] - The company reported a net cash outflow from financing activities of -¥295,197,112.29, compared to a net inflow of ¥13,115,851.12 in the previous year[43] Assets and Liabilities - Total assets decreased to CNY 6,225,434,943.18 from CNY 6,458,522,399.09, a decline of 3.6%[22] - Total current assets decreased to CNY 3,566,392,507.42 from CNY 3,960,606,763.22, reflecting a decline of 9.9%[19] - Total liabilities decreased to CNY 1,647,211,469.83 from CNY 1,932,845,785.58, a reduction of 14.8%[22] - Short-term borrowings decreased significantly to CNY 328,852,473.56 from CNY 621,487,515.16, a reduction of 47.0%[19] Shareholder Information - The total number of common shareholders at the end of the reporting period is 94,019[8] - Major shareholders Zhang Yuchong and Zhang Yuli each hold 10.86% of the shares, totaling 92,640,500 shares[8] - The company’s major shareholders have pledged a total of 11,190,000 shares[8] Product Development and Clinical Trials - The clinical trial for the innovative peptide drug RAY1225 shows promising results, with a half-life approximately twice that of Tirzepatide[11] - RAY1225 is currently undergoing two Phase II clinical studies for obesity and Type 2 diabetes patients[11] - The company completed the first subject enrollment for the Phase II clinical trials in February 2024[11] - The company’s innovative drug RAY1225 is expected to allow for administration every two weeks in clinical use[11] Other Income and Expenses - Other income surged by 154.78% from CNY 1,262,924.89 to CNY 3,217,671.73, attributed to tax incentives for advanced manufacturing[5] - The company reported a 55.70% decrease in income tax expenses, from CNY 23,489,139.13 to CNY 10,405,699.02, influenced by reduced sales revenue and fair value changes of financial assets[5] - The company recorded a fair value change loss of -25,497,155.37 in the current period, contrasting with a gain of 304,988.37 in the previous period[26] - The investment income for the current period is 7,168,129.28, a decrease from 7,708,534.84 in the previous period, reflecting a decline of about 7.0%[26] Capital Raising - The company raised a total of RMB 598,569,999.36 from the issuance of 38,969,401 shares at a price of RMB 15.36 per share[15] - The net amount raised after deducting issuance costs was RMB 590,196,970.39[15] - The new shares issued in June 2023 were listed for trading on July 5, 2023[15]